Blood tests may spot hidden liver damage in diabetics

NCT ID NCT04232293

Completed Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at whether two blood tests, eLIFT and FibroMeter, can accurately detect liver fibrosis (scarring) in people with type 2 diabetes. The researchers compared these blood tests to standard methods like FibroScan and liver biopsy. The goal is to find a simpler, less invasive way to screen for liver damage in this high-risk group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If these blood tests prove accurate, they could offer a simple, non-invasive way to screen for liver fibrosis in people with type 2 diabetes, reducing the need for liver biopsies.
What could go wrong: This is a completed diagnostic study, not a treatment trial. The blood tests may not be accurate enough to replace current methods, and results may not apply to all patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fibrosis metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES MELLITUS, TYPE 2 NAFLD NASH

Contacts and locations

Locations

CHU d'Angers

Angers, 49100, France
CHU de Nantes

Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.